Literature DB >> 17139807

Urotensin-II and cardiovascular diseases.

Nicolas Bousette, Adel Giaid.   

Abstract

Urotensin-II (U-II) is a vasoactive factor with pleiotropic effects. U-II exerts its activity by binding to a G-protein-coupled receptor termed UT. U-II and its receptor are highly expressed in the cardiovascular system. Increased U-II plasma levels have been reported in patients with cardiovascular disease of varying etiologies. We and others have shown that U-II and UT expression is elevated in both clinical and experimental heart failure and atherosclerosis. U-II induces cardiac fibrosis by increasing fibroblast collagen synthesis. In addition, U-II induces cardiomyocyte hypertrophy and increased vascular smooth muscle cell proliferation. We have shown that U-II antagonism using a selective U-II blocker, SB-611812 reduces neointimal thickening and increases lumen diameter in a rat restenosis model of carotid artery angioplasty. These findings suggest an important role for U-II in cardiovascular dysfunction and remodeling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17139807     DOI: 10.1007/s11906-006-0026-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  42 in total

1.  Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.

Authors:  Brigitte Sondermeijer; Andrew Kompa; Paul Komesaroff; Henry Krum
Journal:  Am J Hypertens       Date:  2005-09       Impact factor: 2.689

2.  Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease.

Authors:  C Zoccali; F Mallamaci; G Tripepi; S Cutrupi; P Pizzini; L Malatino
Journal:  Kidney Int       Date:  2006-04       Impact factor: 10.612

3.  Increased plasma levels of Urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis?

Authors:  Ozcan Balat; Fuat Aksoy; Irfan Kutlar; Mete Gurol Ugur; Hakan Iyikosker; Ayse Balat; Rüksen Anarat
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2005-05-01       Impact factor: 2.435

4.  Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats.

Authors:  N Nishikawa; T Masuyama; K Yamamoto; Y Sakata; T Mano; T Miwa; M Sugawara; M Hori
Journal:  J Am Coll Cardiol       Date:  2001-11-01       Impact factor: 24.094

5.  Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study.

Authors:  E Cowley; J P Thompson; P Sharpe; J Waugh; N Ali; D G Lambert
Journal:  Br J Anaesth       Date:  2005-08-26       Impact factor: 9.166

6.  The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease.

Authors:  Matthias Heringlake; Thomas Kox; Orhan Uzun; Barbara Will; Ludger Bahlmann; Stephan Klaus; Sawas Eleftheriadis; Franz Paul Armbruster; Norbert Franz; Ernst Kraatz
Journal:  Regul Pept       Date:  2004-09-15

7.  Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries.

Authors:  Janet J Maguire; Rhoda E Kuc; Katherine E Wiley; Matthias J Kleinz; Anthony P Davenport
Journal:  Peptides       Date:  2004-10       Impact factor: 3.750

8.  Congestive heart failure and expression of myocardial urotensin II.

Authors:  Stephen A Douglas; Lara Tayara; Eliot H Ohlstein; Nadine Halawa; Adel Giaid
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

9.  Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy.

Authors:  Harald Lapp; Guido Boerrigter; Lisa C Costello-Boerrigter; Karsten Jaekel; Thomas Scheffold; Ingo Krakau; Matthias Schramm; Hartmut Guelker; Johannes-Peter Stasch
Journal:  Int J Cardiol       Date:  2004-03       Impact factor: 4.164

10.  The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting.

Authors:  Jianguang Qi; Junbao Du; Xiuying Tang; Jian Li; Bing Wei; Chaoshu Tang
Journal:  Heart Vessels       Date:  2004-03       Impact factor: 2.037

View more
  5 in total

1.  A comparison of assay performance between the calcium mobilization and the dynamic mass redistribution technologies for the human urotensin receptor.

Authors:  Mi Young Lee; Jihye Mun; Jeong Hyun Lee; Sunghou Lee; Byung Ho Lee; Kwang-Seok Oh
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

Review 2.  A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-27       Impact factor: 3.000

3.  The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy.

Authors:  K S Oh; J H Lee; K Y Yi; C J Lim; S Lee; C H Park; H W Seo; B H Lee
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

4.  Urotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the βγ subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C β1 isoform.

Authors:  Yuan Zhang; Jiaoqian Ying; Dongsheng Jiang; Zhigang Chang; Hua Li; Guoqiang Zhang; Shan Gong; Xinghong Jiang; Jin Tao
Journal:  J Biol Chem       Date:  2015-02-12       Impact factor: 5.157

Review 5.  The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.

Authors:  Hélène Castel; Laurence Desrues; Jane-Eileen Joubert; Marie-Christine Tonon; Laurent Prézeau; Marie Chabbert; Fabrice Morin; Pierrick Gandolfo
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-25       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.